MCID: PRL017
MIFTS: 46

Prolymphocytic Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Prolymphocytic Leukemia

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 14 69
Leukemia, Prolymphocytic 42
Leukemia Prolymphocytic 52

Classifications:



External Ids:

Disease Ontology 12 DOID:1039
MeSH 42 D015463
NCIt 47 C3181
UMLS 69 C0023486

Summaries for Prolymphocytic Leukemia

MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to t-cell prolymphocytic leukemia and b cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Development IGF-1 receptor signaling. The drugs Cefepime and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Wikipedia : 72 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Related Diseases for Prolymphocytic Leukemia

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Related Disease Score Top Affiliating Genes
1 t-cell prolymphocytic leukemia 12.4
2 b cell prolymphocytic leukemia 12.4
3 splenic manifestation of prolymphocytic leukemia 11.9
4 leukemia 10.9
5 idiopathic syringomyelia 10.4 MYC TCL1A
6 uterine ligament endometrioid adenocarcinoma 10.4 CD5 MYC
7 primary malignant melanoma of the conjunctiva 10.4 MYC TCL1A
8 chronic lymphocytic leukemia 10.4
9 chest wall lymphoma 10.3 ATM CCND1
10 lymphoma, small cleaved-cell, diffuse 10.3 CD5 ZAP70
11 hemoglobinemia 10.3 CCND1 MYC
12 raynaud disease 10.3 CCND1 CD5
13 lymphoma 10.3
14 estrogen-receptor positive breast cancer 10.3 CD5 MYC
15 gastroesophageal reflux 10.2 CD38 ZAP70
16 metabolic acidosis 10.2 CD38 CD5
17 arteriosclerosis 10.2 CD38 CD5
18 hairy cell leukemia 10.1
19 angiomatous meningioma 10.1 CD38 MYC
20 cd3delta deficiency 10.0 CD5 ZAP70
21 unilateral retinoblastoma 10.0 CCND1 MYC
22 mild hyperphenylalaninemia 10.0 ATM MTCP1 MYC TCL1A
23 t-cell leukemia 10.0
24 drug-induced hepatitis 9.9 CCND1 CD5 MYC
25 hematopoietic stem cell transplantation 9.9
26 mantle cell lymphoma 9.9
27 large granular lymphocyte leukemia 9.9
28 acral lentiginous melanoma 9.9 ADA CD38 MYC
29 hemoglobin c disease 9.9 ADA CCND1 CD5
30 melanoma metastasis 9.9 CCND1 CD5
31 ataxia 9.8
32 kaposi sarcoma 9.8
33 t-cell large granular lymphocyte leukemia 9.8
34 ataxia-telangiectasia 9.8
35 sarcoma 9.8
36 b-cell lymphomas 9.8
37 diffuse large b-cell lymphoma 9.8
38 meningitis 9.8
39 acute allergic sanguinous otitis media 9.8 CCND1 CD38 MYC
40 childhood cerebellar astrocytic neoplasm 9.8 ADA CD38 ZAP70
41 duodenal ulcer 9.7 ATM CD38 CD5 MYC
42 pyridoxine-refractory autosomal recessive sideroblastic anemia 9.7 ATM CCND1 MYC TCL1A
43 megakaryocytic leukemia 9.7 ATM CCND1 CD5 MYC
44 malignant melanocytic peripheral nerve sheath tumor of mediastinum 9.7 CD38 MYC
45 richter's syndrome 9.7
46 acute graft versus host disease 9.7
47 hemolytic anemia 9.7
48 gingivitis 9.7
49 cold agglutinin disease 9.7
50 rhabdomyosarcoma 9.7

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia

Symptoms & Phenotypes for Prolymphocytic Leukemia

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 ABCB4 ADA ATM CCND1 CD38 CD5
2 endocrine/exocrine gland MP:0005379 9.8 ADA ATM CCND1 CD38 MYC ZAP70
3 immune system MP:0005387 9.61 ABCB4 ADA ATM CCND1 CD38 CD5
4 reproductive system MP:0005389 9.1 ABCB4 ADA ATM CCND1 MYC TCL1A

Drugs & Therapeutics for Prolymphocytic Leukemia

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 269)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
6
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
8
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
9
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
11
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
12
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
13
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
14
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
15
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Dalteparin Approved Phase 3 9005-49-6
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
23
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
24
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
25
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
26
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
27 Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
28
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
29
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Cephalosporins Phase 3,Phase 1
34 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
35 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
36 Renal Agents Phase 3,Phase 1,Phase 2
37 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
38 Analgesics Phase 3,Phase 2
39 Anesthetics Phase 3
40 Anesthetics, Dissociative Phase 3
41 Anesthetics, General Phase 3
42 Anesthetics, Intravenous Phase 3
43 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
44 Excitatory Amino Acid Antagonists Phase 3
45 Excitatory Amino Acids Phase 3
46 Neurotransmitter Agents Phase 3
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
49 Dermatologic Agents Phase 3,Phase 2,Phase 1
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)

id Name Status NCT ID Phase Drugs
1 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
4 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
5 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
6 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
7 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
8 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
9 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
10 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
11 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
14 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
15 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Active, not recruiting NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
16 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
17 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
18 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
19 Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) Completed NCT00464633 Phase 2 alvocidib
20 Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Completed NCT00452374 Phase 1, Phase 2 Cytarabine;Fludarabine;Oxaliplatin;Rituximab
21 Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias Completed NCT00472849 Phase 1, Phase 2 Oxaliplatin;Fludarabine;Cytarabine;Rituximab;Pegfilgrastim
22 Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma Completed NCT00006252 Phase 2 fludarabine phosphate;Cyclophosphamide;G-CSF
23 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
24 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
25 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2 Dasatinib (BMS-354825)
26 Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00026351 Phase 2 pentostatin
27 Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma Completed NCT00278161 Phase 2 cyclophosphamide
28 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
29 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) Completed NCT00005626 Phase 2 Irinotecan
30 Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Completed NCT00001637 Phase 2
31 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Completed NCT00782379 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
32 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
33 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
34 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
35 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
36 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
37 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
38 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
39 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
40 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
41 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
42 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Completed NCT01244906 Phase 2
43 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
44 Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed NCT01419691 Phase 2 auranofin
45 Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Recruiting NCT02005289 Phase 2 lenalidomide
46 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
47 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
48 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
49 CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Recruiting NCT02819583 Phase 1, Phase 2
50 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Recruiting NCT02851589 Phase 1, Phase 2

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Genetic Tests for Prolymphocytic Leukemia

Anatomical Context for Prolymphocytic Leukemia

MalaCards organs/tissues related to Prolymphocytic Leukemia:

39
T Cells, B Cells, Bone, Bone Marrow, Liver, Kidney, Myeloid

Publications for Prolymphocytic Leukemia

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 330)
id Title Authors Year
1
The distinctive cytological features of T-cell prolymphocytic leukemia. ( 28120343 )
2017
2
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. ( 28194886 )
2017
3
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
4
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. ( 28232160 )
2017
5
T-cell prolymphocytic leukemia and tuberculosis: a puzzling association. ( 28878921 )
2017
6
Broken heart by T-prolymphocytic leukemia. ( 28775161 )
2017
7
Risk of second cancers in survivors of prolymphocytic leukemia: a SEER data analysis. ( 27924652 )
2017
8
Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. ( 28695755 )
2017
9
Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female. ( 28824253 )
2017
10
A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia. ( 28435655 )
2017
11
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 28377595 )
2017
12
Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion. ( 28819574 )
2017
13
Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. ( 28324286 )
2017
14
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). ( 28379307 )
2017
15
T-cell Prolymphocytic Leukemia. ( 28340878 )
2017
16
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
17
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
18
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 27941777 )
2016
19
PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP. ( 27168399 )
2016
20
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
21
Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report. ( 27757215 )
2016
22
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
23
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
24
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
25
Management of prolymphocytic leukemia. ( 26637744 )
2015
26
T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine. ( 26853400 )
2015
27
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2015
28
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AA Single-Center Experience. ( 26422251 )
2015
29
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
30
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
31
Encephalitozoon hellem in a patient with CD4(+) T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
32
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
33
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
34
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
35
Auer Rod-Like Inclusions in Prolymphocytic Leukemia. ( 26299084 )
2015
36
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2015
37
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
38
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
39
A I^/I' T-cell Receptor Prolymphocytic Leukemia and CD4-/CD8- Double-negative Immunophenotype in a Pediatric Patient. ( 25757027 )
2015
40
Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia. ( 25217890 )
2014
41
Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission. ( 24470149 )
2014
42
Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). ( 25130897 )
2014
43
Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. ( 24764733 )
2014
44
The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. ( 25162594 )
2014
45
An unusual cause of delirium and debility: refractory hypercalcemia in a man with B-cell prolymphocytic leukemia. ( 25333559 )
2014
46
Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. ( 25125625 )
2014
47
T-cell Prolymphocytic Leukemia Frequently Shows Cutaneous Involvement and Is Associated With Gains of MYC, Loss of ATM, and TCL1A Rearrangement. ( 25310835 )
2014
48
B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. ( 24891323 )
2014
49
T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death. ( 25593528 )
2014
50
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia. ( 24762052 )
2014

Variations for Prolymphocytic Leukemia

Expression for Prolymphocytic Leukemia

Search GEO for disease gene expression data for Prolymphocytic Leukemia.

Pathways for Prolymphocytic Leukemia

GO Terms for Prolymphocytic Leukemia

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.63 ADA CD38 MYC
2 response to estradiol GO:0032355 9.54 ABCB4 CCND1 CD38
3 placenta development GO:0001890 9.51 ABCB4 ADA
4 positive regulation of B cell proliferation GO:0030890 9.49 ADA CD38
5 response to morphine GO:0043278 9.48 ABCB4 ADA
6 positive regulation of calcium-mediated signaling GO:0050850 9.43 ADA ZAP70
7 positive regulation of T cell differentiation GO:0045582 9.4 ADA ZAP70
8 response to vitamin E GO:0033197 9.32 ADA CCND1
9 response to hypoxia GO:0001666 9.26 ABCB4 ADA ATM CD38
10 positive regulation of alpha-beta T cell differentiation GO:0046638 9.16 ADA ZAP70
11 response to drug GO:0042493 9.02 ABCB4 ADA CCND1 CD38 MYC
12 positive regulation of response to DNA damage stimulus GO:2001022 8.96 MYC

Sources for Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....